Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Gilson H, Schakman O, Kalista S, et al.
American Journal of Physiology-Endocrinology and Metabolism
Summary
Revealed that follistatin-induced muscle hypertrophy occurs through dual mechanisms: satellite cell proliferation and simultaneous inhibition of both myostatin and activin signaling. Demonstrated that follistatin's effects extend beyond simple myostatin antagonism.
Key Findings
- Follistatin induced significant muscle hypertrophy through satellite cell activation
- Inhibited both myostatin and activin, not myostatin alone
- Satellite cell proliferation was essential for the full hypertrophic response
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
Kota J, Handy CR, Haidet AM, et al.
Science Translational Medicine
Demonstrated that AAV-mediated follistatin gene delivery produced significant and sustained increases in muscle mass and strength in nonhuman primates. This was the first primate study to confirm follistatin's myostatin-inhibiting muscle growth effects translate beyond rodent models.
- Follistatin gene delivery increased muscle size and strength in cynomolgus macaques
- Effects were sustained over long-term follow-up without adverse effects
Regulation of myostatin activity and muscle growth
Lee SJ, McPherron AC
Proceedings of the National Academy of Sciences
Foundational study establishing that follistatin is a potent endogenous inhibitor of myostatin. Transgenic mice overexpressing follistatin exhibited dramatic increases in muscle mass exceeding those seen in myostatin knockout animals, suggesting follistatin inhibits additional negative regulators of muscle growth.
- Follistatin overexpression produced muscle mass increases exceeding myostatin knockout alone
- Established follistatin as a natural myostatin antagonist in vivo